Attention: this website and our services will be terminated in the near future. A new webiste with even more statistical calculators will take its place.


  1. Biology, detection, and clinical implications of circulating tumor cells.
    Joosse SA
    , Gorges TM, Pantel K

    EMBO Mol Med. 2014 Nov;pii: e201303698

  2. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases.
    Joosse SA
    , Müller V, Steinbach B, Pantel K, Schwarzenbach H

    Br J Cancer. 2014 Aug;111(5):909-17

  3. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.
    Babayan A, Hannemann J, Spötter J, Müller V, Pantel K,
    Joosse SA

    PLoS One. 2013 Sep;18;8(9):e75038

  4. Biological challenges in the detection of circulating tumor cells.
    Joosse SA
    , Pantel K

    Cancer Res. 2013 Jan;73(1):8-11

  5. BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.
    Joosse SA

    Nat Rev Cancer. 2012 May;12(5):372

  6. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH
    Joosse SA
    , Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM

    Breast Cancer Res Treat. 2012 Apr;132(2):379-89

  7. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.
    Joosse SA
    , Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K

    Clin Cancer Res. 2012 Feb;18(4):993-1003

  8. Quantitative high-resolution genomic analysis of single cancer cells.
    Hannemann J, Meyer-Staeckling S, Kemming D, Alpers I,
    Joosse SA
    , Pospisil H, Kurtz S, Görndt J, Püschel K, Riethdorf S, Pantel K, Brandt B

    PLoS One. 2011 Nov;6(11):e26362

  9. A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
    Didraga MA, van Beers EH,
    Joosse SA
    , Brandwijk KI, Oldenburg RA, Wessels LF, Hogervorst FB, Ligtenberg MJ, Hoogerbrugge N, Verhoef S, Devilee P, Nederlof PM.

    Breast Cancer Res Treat. 2011 Nov;130(2):425-36

  10. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
    Joosse SA
    , Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM.

    Genes Chromosomes Cancer. 2011 Feb;50(2):71-81

  11. Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.
    Bruin SC, Klijn C, Liefers GJ, Braaf LM,
    Joosse SA
    , van Beers EH, Verwaal VJ, Morreau H, Wessels LF, van Velthuysen ML, Tollenaar RA, Van't Veer LJ

    BMC Cancer. 2010 Dec 2;10:662

  12. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
    Holstege H, van Beers E, Velds A, Liu X,
    Joosse SA
    , Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J.

    BMC Cancer. 2010 Aug 24;10:455

  13. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients.
    Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E,
    Joosse SA
    , Klijn C, Nederlof PM, Reinders MJ, Wessels LF, van de Vijver MJ

    Clin Cancer Res. 2010 Jan;16(2):651-63

  14. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
    Puppe J, Drost R, Liu X,
    Joosse SA
    , Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM

    Breast Cancer Res. 2009;11(4):R63

  15. Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality.
    van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Brüggenwirth HT, Withagen-Hermans CJ, Collée JM,
    Joosse SA
    , Terlouw-Kromosoeto JN, Nederlof PM

    Genet Test Mol Biomarkers. 2009 Jun;13(3):399-406

  16. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer.
    Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S,
    Joosse SA
    , Vahteristo P, Kiuru M, Karhu A, Sammalkorpi H, Vanharanta S, Lehtonen R, Edgren H, Nederlof PM, Hietala M, Aittomäki K, Herva R, Knuutila S, Aaltonen LA, Launonen V.

    Genes Chromosomes Cancer. 2009 Jul;48(7):544-51

  17. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H,
    Joosse SA
    , van Oostrom CT, Nederlof PM, de Vries A, Jonkers J

    Cancer Res. 2009 Apr;69(8):3625-33

  18. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
    Joosse SA
    , van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM

    Breast Cancer Res Treat. 2009 Aug;116(3):479-89

  19. ESR1 gene amplification in breast cancer: a common phenomenon?
    Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K,
    Joosse SA
    , Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ

    Nat Genet. 2008 Jul;40(7):807-8; author reply 810-2

  20. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH,
    Joosse SA
    , Wong N, Novak D, Quenneville LA, Grist SA; kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD

    Eur J Hum Genet. 2008 Jul;16(7):820-32

  21. Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material.
    Joosse SA
    , van Beers EH, Nederlof PM

    BMC Cancer. 2007 Mar;7:43

  22. A multiplex PCR predictor for aCGH success of FFPE samples.
    van Beers EH,
    Joosse SA
    , Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, Nederlof PM

    Br J Cancer. 2006 Jan;94(2):333-7